Commentary: Advocating for patient and public involvement and engagement in health economic evaluation.

Autor: Staniszewska, Sophie, Jakab, Ivett, Low, Eric, Mossman, Jean, Posner, Phil, Husereau, Don, Stephens, Richard, Drummond, Michael

Publikováno v: Research Involvement & Engagement; 7/3/2023, Vol. 9 Issue 1, p1-5, 5p

Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

Roadmap to 2030 for Drug Evaluation in Older Adults.

Autor: Liu Q; Office of Clinical Pharmacology, Office of Translational Sciences, Center for Drug Evaluation and Research, US Food and Drug Administration, Silver Spring, Maryland, USA., Schwartz JB; Departments of Medicine, Bioengineering and Therapeutic Sciences, University of California San Francisco, San Francisco, California, USA., Slattum PW; Department of Pharmacotherapy and Outcomes Science and Virginia Center on Aging, Virginia Commonwealth University, Richmond, Virginia, USA., Lau SWJ; Office of Clinical Pharmacology, Office of Translational Sciences, Center for Drug Evaluation and Research, US Food and Drug Administration, Silver Spring, Maryland, USA., Guinn D; Office of Clinical Pharmacology, Office of Translational Sciences, Center for Drug Evaluation and Research, US Food and Drug Administration, Silver Spring, Maryland, USA., Madabushi R; Office of Clinical Pharmacology, Office of Translational Sciences, Center for Drug Evaluation and Research, US Food and Drug Administration, Silver Spring, Maryland, USA., Burckart G; Office of Clinical Pharmacology, Office of Translational Sciences, Center for Drug Evaluation and Research, US Food and Drug Administration, Silver Spring, Maryland, USA., Califf R; Verily and Google Health (Alphabet), South San Francisco, California, USA., Cerreta F; Portfolio office, European Medicines Agency (EMA), Amsterdam, The Netherlands., Cho C; Oncology Early Development and Translational Research, Merck & Co., Kenilworth, New Jersey, USA., Cook J; Department of Clinical Pharmacology, Pfizer Global Research and Development, Groton, Connecticut, USA., Gamerman J; Office of Medical Policy, Center for Drug Evaluation and Research, US Food and Drug Administration, Silver Spring, Maryland, USA., Goldsmith P; Lilly Exploratory Medicine and Pharmacology, Bracknell, UK., van der Graaf PH; Certara, Canterbury, UK., Gurwitz JH; Meyers Health Care Institute, a joint endeavor of University of Massachusetts Medical School, Reliant Medical Group, and Fallon Health, Worcester, Massachusetts, USA., Haertter S; Boehringer Ingelheim Pharma, Translational Medicine & Clinical Pharmacology, Ingelheim, Germany., Hilmer S; Kolling Institute, University of Sydney and Royal North Shore Hospital, St. Leonards, New South Wales, Australia., Huang SM; Office of Clinical Pharmacology, Office of Translational Sciences, Center for Drug Evaluation and Research, US Food and Drug Administration, Silver Spring, Maryland, USA., Inouye SK; Marcus Institute for Aging Research, Hebrew SeniorLife and Harvard Medical School, Boston. Massachusetts, USA., Kanapuru B; Oncology Center of Excellence, US Food and Drug Administration, Silver Spring, Maryland, USA., Pirmohamed M; Wolfson Centre for Personalised Medicine, University of Liverpool, Liverpool, UK., Posner P; Patient-Centered Outcomes Research Institute Ambassador, Gainesville, Florida, USA., Radziszewska B; National Institute of Aging, National Institute of Health, Bethesda, Maryland, USA., Keipp Talbot H; Departments of Medicine and Public Health, Vanderbilt University Medical Center, Nashville, Tennessee, USA., Temple R; Center for Drug Evaluation and Research, U.S. Food and Drug Administration, Silver Spring, Maryland, USA.

Publikováno v: Clinical pharmacology and therapeutics [Clin Pharmacol Ther] 2022 Aug; Vol. 112 (2), pp. 210-223. Date of Electronic Publication: 2021 Nov 08.